ChromaDex Debuts Clinical Strength Tru Niagen Pro 1,000mg Featuring Niagen, One Of The Most Efficient Nicotinamide Adenine Dinucleotide Boosters Available, To Consumers Nationwide
Portfolio Pulse from Benzinga Newsdesk
ChromaDex Corp. (NASDAQ:CDXC) has launched its clinical strength Tru Niagen® Pro 1,000mg, a Nicotinamide Adenine Dinucleotide (NAD+) booster, to consumers nationwide. The product is recommended by physicians and used by pro-athletes as it is clinically proven to boost NAD+ levels by up to 150% in as little as three weeks. The product is also Certified for Sport® by NSF International, a certification program recognized by the United States Anti-Doping Agency (USADA), Major League Baseball (MLB), and the National Hockey League (NHL).
November 01, 2023 | 12:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ChromaDex's new product, Tru Niagen® Pro 1,000mg, could potentially increase the company's revenue as it is clinically proven and recommended by physicians and pro-athletes. The product's certification by NSF International also adds credibility.
The launch of a new product that is clinically proven and recommended by physicians and pro-athletes could potentially increase ChromaDex's revenue. The product's certification by NSF International, a recognized certification program, adds credibility and could attract more consumers, thereby increasing sales.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100